Sudarshan Pharma Industries Share Price
38.70-0.32 (-0.82%)
+22.94% past 1 Year
Sudarshan Pharma Industries Limited is engaged in contract manufacturing, outsource & Supply of Generic Pharma formulation and medicines to healthcare institution, Government, NGO and Hospitals. It outsource its manufacturing facility,
Corporate filings & documents
Announcements
Please find enclosed the newpaper advertisement for the Notice of 18th Annual General Meeting to be held on Yesday 22nd September 2026 at 3.00 pm published in (1) Mumbai Lakshdeep (Marathi) and (2) Financial Express (English).
3 days agoPlease find enclosed the newpaper advertisement for the Notice of 18th Annual General Meeting to be held on Yesday 22nd September 2026 at 3.00 pm published in (1) Mumbai Lakshdeep (Marathi) and (2) Financial Express (English).
3 days agoPursuant to Reg 34 of SEBI Listing Regulations please find enclosed the Annual Report of the Company for the FY 2025-26.
6 days agoPursuant to Reg 34 of SEBI Listing Regulations please find enclosed the Annual Report of the Company for the FY 2025-26.
6 days agoPursuant to Reg 34 of SEBI Listing Regulations please find enclosed the Annual Report of the Company for the FY 2025-26.
6 days agoPursuant to Reg 34 of SEBI Listing Regulations please find enclosed the Annual Report of the Company for the FY 2025-26.
6 days agoPursuant to Regulation 34 of SEBI Listing Regulations please find enclosed the Notice of 18th Annual General Meeting to be held on Tuesday 22/September/2026.
6 days agoPursuant to Regulation 34 of SEBI Listing Regulations please find enclosed the Notice of 18th Annual General Meeting to be held on Tuesday 22/September/2026.
6 days agoThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on August 26 2026 for Hemal V Mehta & Sachin V Mehta
1 week agoThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on August 26 2026 for Hemal V Mehta & Sachin V Mehta
1 week agoThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on August 21 2026 for Hemal V Mehta & Sachin V Mehta
1 week agoThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on August 21 2026 for Hemal V Mehta & Sachin V Mehta
1 week agoIt is hereby informed that the members of the FCCB COmmittee of the COmpany have at their meeting held today 19/Aug/2026 have approved allotment of 48 11 730 fully paid-up equity shares of Re.1/- each upon conversion of Foreign Currency Convertible Bonds worth US$15 00 000.
2 weeks agoIt is hereby informed that the members of the FCCB COmmittee of the COmpany have at their meeting held today 19/Aug/2026 have approved allotment of 48 11 730 fully paid-up equity shares of Re.1/- each upon conversion of Foreign Currency Convertible Bonds worth US$15 00 000.
2 weeks agoPlease find enclosed the newspaper advertisement for the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30/June/2026 published in (i) Mumbai Lakshdeep (Marathi) and (ii) Financial Express (English).
2 weeks agoPlease find enclosed the newspaper advertisement for the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30/June/2026 published in (i) Mumbai Lakshdeep (Marathi) and (ii) Financial Express (English).
2 weeks agoPursuant to Regulation 30 of SEBI LODR Regulations We hereby submit the updated Investor Presentation
2 weeks agoPursuant to Regulation 30 of SEBI LODR Regulations We hereby submit the updated Investor Presentation
2 weeks agoThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on August 14 2026 for Vasantrai Ratilal Mehta Jatin Vasantrai Mehta Hemal V Mehta HUF Mrs. Devangi Hemal Mehta Sachin V Mehta HUF and Mrs. Namrata Sachin Mehta
2 weeks agoThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on August 14 2026 for Vasantrai Ratilal Mehta Jatin Vasantrai Mehta Hemal V Mehta HUF Mrs. Devangi Hemal Mehta Sachin V Mehta HUF and Mrs. Namrata Sachin Mehta
2 weeks agoA Meeting of the FCCB Committee of the Company is scheduled on Wednesday 19-August-2026 to consider and approve conversion a portion of funds raised through FCCBs into equity shares and allotment thereof.
2 weeks agoA Meeting of the FCCB Committee of the Company is scheduled on Wednesday 19-August-2026 to consider and approve conversion a portion of funds raised through FCCBs into equity shares and allotment thereof.
2 weeks agoWe hereby submit the presentation on the manufacturing plant proposed to be acquired by the Company.
3 weeks agoWe hereby submit the presentation on the manufacturing plant proposed to be acquired by the Company.
3 weeks agoThe Company has entered into a Memorandum of Understanding to acquire 1 24 64 000 equity shares of Rs.10/- each of the target company (76% of paid up equity share capital). The acquisition includes acquisition of business manufacturing plant and the team subject to due diligence and other regulatory approvals. Upon completion of the acquistion the target company would become a subsidiary of the Company.
3 weeks agoThe Company has entered into a Memorandum of Understanding to acquire 1 24 64 000 equity shares of Rs.10/- each of the target company (76% of paid up equity share capital). The acquisition includes acquisition of business manufacturing plant and the team subject to due diligence and other regulatory approvals. Upon completion of the acquistion the target company would become a subsidiary of the Company.
3 weeks agoThe Board of Directors at their Meeting held on 12/August/2026 approved the divestment of 2 09 100 equity shares (51.00% of paid up share capital) of Ishwari Healthcare Private Limited. Upon completion of divestment Ishwari Healthcare Private Limited would cease to be a subsidairy of the Company.
3 weeks agoThe Board of Directors at their Meeting held on 12/August/2026 approved the divestment of 2 09 100 equity shares (51.00% of paid up share capital) of Ishwari Healthcare Private Limited. Upon completion of divestment Ishwari Healthcare Private Limited would cease to be a subsidairy of the Company.
3 weeks agoThe Board of Directors at their meeting held on 12/August/2026 approved to acquire 3 000 equity shares (30.00% of paid up capital) of Sudarshan Maven Pharma Private Limited. Upon acqusition Sudarshan Maven Pharma Private Limited would become a wholly-owned subsidiary of the Company.
3 weeks agoThe Board of Directors at their meeting held on 12/August/2026 approved to acquire 3 000 equity shares (30.00% of paid up capital) of Sudarshan Maven Pharma Private Limited. Upon acqusition Sudarshan Maven Pharma Private Limited would become a wholly-owned subsidiary of the Company.
3 weeks agoPlease find attached the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30/06/2026
3 weeks agoPlease find attached the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30/06/2026
3 weeks agoThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on August 08 2026 for Hemal Vasantrai Mehta
3 weeks agoThe Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on August 08 2026 for Hemal Vasantrai Mehta
3 weeks agoSudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results for the quarter ended 30/June/2026.
3 weeks agoSudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 inter alia to consider and approve Unaudited Standalone and Consolidated Financial Results for the quarter ended 30/June/2026.
3 weeks agoThe Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on July 14 2026 for Hemal Vasantrai Mehta
1 month agoThe Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 on July 14 2026 for Hemal Vasantrai Mehta
1 month agoPlease find attached copy of certificates under Regulation 74(5) of SEBI (Depository And Participants) Regulations 2018 received from Kfin Technologies Limited for the quarter ended 30/June/2026.
1 month agoPlease find attached copy of certificates under Regulation 74(5) of SEBI (Depository And Participants) Regulations 2018 received from Kfin Technologies Limited for the quarter ended 30/June/2026.
1 month agoThe Trading Window of the Company shall remain closed with effect from 01/July/2026 untill the expiry of 48 hours after the declaration of the financial results for the quarter ended 30/June/2026.
2 months agoThe Trading Window of the Company shall remain closed with effect from 01/July/2026 untill the expiry of 48 hours after the declaration of the financial results for the quarter ended 30/June/2026.
2 months agoPlease find enclosed the Scrutinizers Report on the business transacted through postal ballot notice dated 21/May/2026 which was open for voting from 26/May/2026 to 24/June/2026.
2 months agoPlease find enclosed the Scrutinizers Report on the business transacted through postal ballot notice dated 21/May/2026 which was open for voting from 26/May/2026 to 24/June/2026.
2 months agoPlease find enclosed the voting results on the business transacted through postal ballot notice dated 21/May/2026 which was open for voting from 26/May/2026 to 24/June/2026.
2 months agoPlease find enclosed the voting results on the business transacted through postal ballot notice dated 21/May/2026 which was open for voting from 26/May/2026 to 24/June/2026.
2 months agoWe would like to inform you that the Meeting of the Board of Directors of the COmpany scheduled today Thursday 18/June/2026 stands cancelled due to unavoidable reasons.
2 months agoWe would like to inform you that the Meeting of the Board of Directors of the COmpany scheduled today Thursday 18/June/2026 stands cancelled due to unavoidable reasons.
2 months agoSudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/06/2026 inter alia to consider and approve proposal for raising of funds by way of issue of one or more instruments through private placement / preferential issue or such method or combination thereof subject to statutory / regulatory approvals as may be necessary.
2 months agoSudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/06/2026 inter alia to consider and approve proposal for raising of funds by way of issue of one or more instruments through private placement / preferential issue or such method or combination thereof subject to statutory / regulatory approvals as may be necessary.
2 months agoAnnual reports
Concalls & investor presentations
Aug 2026
ConcallPresentation
Apr 2026
ConcallPresentation
Jan 2026
ConcallPresentation
Apr 2025
ConcallPresentation
Oct 2024
ConcallPresentation
May 2024
ConcallPresentation
Nov 2023
ConcallPresentation
May 2023
ConcallPresentation
Corporate Actions
Date
Type
Details
2024-11-22
Split
10:1
2023-08-25
Dividend
0.3
Company details
Registered office
301 3rd Floor Aura Biplex Above Kalyan Jewellers S V Road Borivali (West) Mumbai Maharashtra PIN: 400092 Tel No: 022-42221111 / 43331111 / 42221116 Fax No: NULL Email: [email protected] Internet: www.sudarshanpharma.com
Registrars
PIN: Tel No: Fax No: Email:
Management
Nirav Shah, Company Secretary & Compliance Officer
Hemal Vasantrai Mehta, Chairman & Managing Director
Hemal Vasantrai Mehta, Chairman & Managing Director
Jaya Ankur Singhania, Non Executive Independent Director
Rushabh P Patil, Non Executive Independent Director
Anil George, Non Executive Director
Vijay Ojha, Independent Director
Vinay Pandey, Non Executive Director
Sanat Bhat, Independent Director
Details
BSE 543828
NSE NULL
ISIN INE00TV01023